At the time of writing, shares of ImpediMed Limited [ASX:IPD] are up by 14.44% from this morning’s open, trading at 51 cents in today’s market.
ImpediMed is a global company founded in Brisbane, Australia, with US and European operations. It is a world leader in the design and manufacturing of advanced medical products which use bioimpedance spectroscopy technology (BIS).
What caused ImpediMed shares to rise?
Two of ImpediMed’s products featured prominently at The Australasian Lymphology Association (ALA) conference held from May 17–19 this year may have contributed to their share value growth. After record attendance at that conference, things have only continued to improve for ImpediMed.
Leonie Naumann, President of the Australasian Lymphology Association, said:
‘We are delighted to report that the 12th ALA conference, like the association has enjoyed very strong growth over the last four years. The ALA enjoys increasingly strong support from industry, including ImpediMed one of the ALA’s industry Partners.’
The two key ImpediMed products featured were the ‘L-Dex’ and ‘Sozo’. Both medical diagnostic devices that allow aspects of a patient’s body to be scanned and monitored non-invasively.
What next for ImpediMed?
With higher cash flows forecasted for the company, and profit expected to continue growing over the next couple of years, the future of ImpediMed seems bright.
For Money Morning
PS: Looking for ASX-listed stocks with the potential to explode upward in price? Money Morning editor Sam Volkering argues that the greatest gains can be made in the small, obscure stocks that most investors have never heard of…yet. He’s authored a free report looking at three stocks that could have the potential to go from unknown to household names. Find out more in this free report ‘Top Three Aussie Stocks to Own in 2018’.